Treatment with an anti EGFR Antibody of IgG class and with a Humanized Antibody against receptor for insulin-like growth factor 1

摘要

This application provides an Antibody anti EGFR (epidermal growth factor receptor) and a class of LGG Antibody Humanized igf-1r for Combined use in the treatment of cancer, with or without additional agents or treatments, such as other Anticancer Drugs Or Radiation Therapy.The application also includes a Pharmaceutical composition comprising a combination of an anti EGFR Antibody and IgG Class Antibody Humanized igf-1r in a pharmaceutically acceptable Carrier.Claim 1: anti EGFR Antibody IgG Antibody and Humanized igf-1r for Combined use in the treatment of cancer, in which the anti EGFR Antibody Class TGG comprises: (a) in the heavy chain variable Domain, a sequence id no. 1 SEC CDR1, CDR2 of seq Ncia SEC ID no. 16, and CDR3 Sequence SEC ID no 31, and (b) in the variable domain of light chainA sequence id no. 33 sec CDR1, CDR2 Sequence SEC ID no 34, and CDr3 sequence id no. 35 sec.